Official Title
A Retrospective Study of the Effect of Antiviral Drugs on the Treatment of SARS-CoV-2 COVID19
Brief Summary
Retrospective Non-Randomized Analytical Cohort Study of Completed SARS-CoV2 COVID19 Cases
Detailed Description
Analyzing the case histories of patients with SARS-CoV2 COVID19 infection and the impact on
the outcomes of prescribing antiviral drugs
Recruiting
Complication of Medical Care
Pneumonia, Viral
Drug: Favipiravir
Antiviral drugs
Drug: Remdesivir
Antiviral drugs
Eligibility Criteria
Inclusion Criteria:
main group
- Patients with COVID19 with medium and easy condition disease
- take favipiravir/remdisivir control group
- Patients with COVID19 with medium and easy condition disease
- not take favipiravir/remdisivir
Exclusion Criteria:
- patients younger 18
- severe conditionis
Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Kazakhstan
Locations
Aidos Konkaev
Nur-Sultan, Kazakhstan
Semey Medical University
Semey, Kazakhstan
Astana Medical University
NCT Number
MeSH Terms
Pneumonia, Viral
Remdesivir
Favipiravir